Cambridge Innovation Capital
Tim Garnett has over thirty years of experience in the pharmaceutical Industry in both the United Kingdom and the United States, most recently as Chief Medical Officer of Eli Lilly and Company from 2008 to 2021. He has been involved in the development of multiple drugs through early and late phase clinical development and regulatory approval as well as heading up Lilly’s drug safety function prior to becoming Chief Medical Officer and was formerly the Chair of the R&D Leadership Forum for Pharmaceutical Research and Manufacturers of America (PhRMA).
He graduated in Medicine from St. George’s Hospital Medical School and specialized in Obstetrics and Gynaecology becoming a Member then Fellow of the Royal College of Obstetricians and Gynaecologists.
Dr. Garnett retired from Eli Lilly in 2021 and now sits as a Board member of several innovative pharmaceutical companies in the US and Europe.
This person is not in the org chart
This person is not in any offices
Cambridge Innovation Capital
CIC backs life sciences and technology companies in Europe’s leading ecosystem, Cambridge. A preferred investor for the university.